Trend — Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) (J0717) in Medicare, the United States

The full twelve-year services and payments series for this market — per-year values, with the FFS-enrollment denominator beside each.

The compound annual growth for J0717 in the United States — endpoints exclude the introduction year; an Exclude 2020–21 view drops the pandemic years too.